BWA
TGTX icon

Boulder Wealth Advisors’s TG Therapeutics TGTX Stock Holding History

Boulder Wealth Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2K Buy
+200
New +$1.45K ﹤0.01% 116

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Boulder Wealth Advisors's TGTX Position: Q4 2022 in Review

Boulder Wealth Advisors opened a new position in TG Therapeutics (TGTX) in Q4 2022: 200 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #116 among its holdings.

198 funds tracked by Wall St. Rank hold TGTX as of Q4 2022.

  • Boulder Wealth Advisors held 200 shares of TG Therapeutics worth $2K as of Q4 2022.
  • TG Therapeutics was a new Boulder Wealth Advisors position in Q4 2022.
  • TG Therapeutics made up ﹤0.01% of Boulder Wealth Advisors's portfolio in Q4 2022, its #116 holding.
  • 198 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2022.

Based on Boulder Wealth Advisors's 13F filing for Q4 2022, filed 21 Feb 2023.